ICU Medical, Inc. $ICUI Shares Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. raised its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 129.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,588 shares of the medical instruments supplier’s stock after purchasing an additional 4,842 shares during the quarter. Fox Run Management L.L.C.’s holdings in ICU Medical were worth $1,030,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. SJS Investment Consulting Inc. lifted its holdings in shares of ICU Medical by 41,000.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 410 shares during the period. Covestor Ltd grew its holdings in ICU Medical by 70.7% during the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 236 shares during the period. Smartleaf Asset Management LLC raised its position in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after acquiring an additional 101 shares in the last quarter. Headlands Technologies LLC acquired a new stake in ICU Medical in the second quarter valued at $177,000. Finally, AlphaQuest LLC boosted its position in shares of ICU Medical by 3,058.3% during the 2nd quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock worth $200,000 after purchasing an additional 1,468 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ICUI has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday, February 15th. Piper Sandler increased their target price on shares of ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Finally, KeyCorp lifted their price target on shares of ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $179.33.

ICU Medical Price Performance

ICU Medical stock opened at $155.12 on Thursday. The firm has a market capitalization of $3.83 billion, a PE ratio of 7,759.88, a P/E/G ratio of 2.16 and a beta of 0.79. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $160.29. The firm’s 50-day simple moving average is $149.75 and its 200 day simple moving average is $136.55. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.68 by $0.23. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. The company had revenue of $535.94 million during the quarter, compared to analysts’ expectations of $541.20 million. During the same quarter in the previous year, the business posted $2.11 earnings per share. The firm’s quarterly revenue was down 14.1% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, equities research analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.